299 related articles for article (PubMed ID: 23720090)
1. Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: protease inhibitors and NSAIDs in a meta-analysis.
Yuhara H; Ogawa M; Kawaguchi Y; Igarashi M; Shimosegawa T; Mine T
J Gastroenterol; 2014 Mar; 49(3):388-99. PubMed ID: 23720090
[TBL] [Abstract][Full Text] [Related]
2. Post-ERCP pancreatitis.
Arata S; Takada T; Hirata K; Yoshida M; Mayumi T; Hirota M; Yokoe M; Hirota M; Kiriyama S; Sekimoto M; Amano H; Wada K; Kimura Y; Gabata T; Takeda K; Kataoka K; Ito T; Tanaka M
J Hepatobiliary Pancreat Sci; 2010 Jan; 17(1):70-8. PubMed ID: 20012323
[TBL] [Abstract][Full Text] [Related]
3. Nafamostat mesilate for prevention of post-ERCP pancreatitis: a meta-analysis of prospective, randomized, controlled trials.
Yu G; Li S; Wan R; Wang X; Hu G
Pancreas; 2015 May; 44(4):561-9. PubMed ID: 25822153
[TBL] [Abstract][Full Text] [Related]
4. Comparison between ulinastatin and nafamostat for prevention of post-endoscopic retrograde cholangiopancreatography complications: a prospective, randomized trial.
Park JY; Jeon TJ; Hwang MW; Sinn DH; Oh TH; Shin WC; Choi WC
Pancreatology; 2014; 14(4):263-7. PubMed ID: 25062874
[TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial for efficacy of nafamostat mesilate in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis.
Ohuchida J; Chijiiwa K; Imamura N; Nagano M; Hiyoshi M
Pancreas; 2015 Apr; 44(3):415-21. PubMed ID: 25479585
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of gabexate mesilate in preventing post endoscopic retrograde cholangiopancreatography pancreatitis: A meta-analysis of randomized clinical trials.
Chiu YJ; Chen SC; Kang YN; Hou SK; Chao CC; Chang CC
J Formos Med Assoc; 2021 Apr; 120(4):1090-1099. PubMed ID: 33183879
[TBL] [Abstract][Full Text] [Related]
7. Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?
Park KT; Kang DH; Choi CW; Cho M; Park SB; Kim HW; Kim DU; Chung CW; Yoon KT
Pancreas; 2011 Nov; 40(8):1215-9. PubMed ID: 21775918
[TBL] [Abstract][Full Text] [Related]
8. What is impact of nonsteroidal anti-inflammatory drugs in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials.
Lyu Y; Cheng Y; Wang B; Xu Y; Du W
BMC Gastroenterol; 2018 Jul; 18(1):106. PubMed ID: 29973142
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rectal nonsteroidal anti-inflammatory drugs for prophylaxis against post-ERCP pancreatitis: a systematic review and meta-analysis.
Hou YC; Hu Q; Huang J; Fang JY; Xiong H
Sci Rep; 2017 Apr; 7():46650. PubMed ID: 28440297
[TBL] [Abstract][Full Text] [Related]
10. Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and network meta-analysis.
Akshintala VS; Sperna Weiland CJ; Bhullar FA; Kamal A; Kanthasamy K; Kuo A; Tomasetti C; Gurakar M; Drenth JPH; Yadav D; Elmunzer BJ; Reddy DN; Goenka MK; Kochhar R; Kalloo AN; Khashab MA; van Geenen EJM; Singh VK
Lancet Gastroenterol Hepatol; 2021 Sep; 6(9):733-742. PubMed ID: 34214449
[TBL] [Abstract][Full Text] [Related]
11. Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis based on prospective, randomized, and controlled trials.
Xie Y; Cheng Z; Deng C; Deng M; Zhang H
Medicine (Baltimore); 2023 Oct; 102(41):e35174. PubMed ID: 37832051
[TBL] [Abstract][Full Text] [Related]
12. Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study.
Andriulli A; Caruso N; Quitadamo M; Forlano R; Leandro G; Spirito F; De Maio G
JOP; 2003 Jan; 4(1):41-8. PubMed ID: 12555015
[TBL] [Abstract][Full Text] [Related]
13. Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials.
Zheng M; Chen Y; Yang X; Li J; Zhang Y; Zeng Q
BMC Gastroenterol; 2007 Feb; 7():6. PubMed ID: 17295917
[TBL] [Abstract][Full Text] [Related]
14. Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study.
Fujishiro H; Adachi K; Imaoka T; Hashimoto T; Kohge N; Moriyama N; Suetsugu H; Kawashima K; Komazawa Y; Ishimura N; Ishihara S; Amano Y; Kinoshita Y
J Gastroenterol Hepatol; 2006 Jun; 21(6):1065-9. PubMed ID: 16724996
[TBL] [Abstract][Full Text] [Related]
15. Rectal nonsteroidal anti-inflammatory drugs administration is effective for the prevention of post-ERCP pancreatitis: An updated meta-analysis of randomized controlled trials.
Yang C; Zhao Y; Li W; Zhu S; Yang H; Zhang Y; Liu X; Peng N; Fan P; Jin X
Pancreatology; 2017; 17(5):681-688. PubMed ID: 28734720
[TBL] [Abstract][Full Text] [Related]
16. [Could nafamostat or gabexate prevent the post endoscopic retrograde cholangiopancreatography pancreatitis?].
Kwon YH; Kim JY; Lee SJ; Jang SY; Park HW; Yang HM; Jung MK; Jeon SW; Cho CM; Tak WY; Kweon YO; Kim SK
Korean J Gastroenterol; 2012 Mar; 59(3):232-8. PubMed ID: 22460572
[TBL] [Abstract][Full Text] [Related]
17. The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis.
Kim JS; Lee SH; Park N; Huh G; Chun JW; Choi JH; Cho IR; Paik WH; Ryu JK; Kim YT
BMC Gastroenterol; 2022 May; 22(1):271. PubMed ID: 35641898
[TBL] [Abstract][Full Text] [Related]
18. Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized, double-blind, controlled trial.
Yoo KS; Huh KR; Kim YJ; Kim KO; Park CH; Hahn T; Park SH; Kim JH; Park CK; Kwon YJ; Lehman GA
Pancreas; 2011 Mar; 40(2):181-6. PubMed ID: 21206331
[TBL] [Abstract][Full Text] [Related]
19. Pre-endoscopic retrograde cholangiopancreatography (ERCP) administration of rectal indomethacin in unselected patients to reduce post-ERCP pancreatitis: A systematic review and meta-analysis.
Garg R; Mohan BP; Krishnamoorthi R; Rustagi T
Indian J Gastroenterol; 2018 Mar; 37(2):120-126. PubMed ID: 29619673
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis.
Andriulli A; Leandro G; Niro G; Mangia A; Festa V; Gambassi G; Villani MR; Facciorusso D; Conoscitore P; Spirito F; De Maio G
Gastrointest Endosc; 2000 Jan; 51(1):1-7. PubMed ID: 10625786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
